STOCK TITAN

Vanda Pharmaceuticals Inc - VNDA STOCK NEWS

Welcome to our dedicated news page for Vanda Pharmaceuticals (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vanda Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vanda Pharmaceuticals's position in the market.

Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) has received a partial denial from the United States Court of Federal Claims for the FDA's uncompensated taking of Vanda's trade secrets and confidential information. The claim filed in May 2023 seeks compensation for the FDA's improper communication and disclosure of trade secrets to certain generic drug manufacturers. The Court's decision on January 18, 2024, allows Vanda's takings claim to move forward, with the company now intending to engage in discovery to support its claims.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
-
Rhea-AI Summary
Vanda Pharmaceuticals Inc. announced the publication of a study on the efficacy and safety of Iloperidone in treating bipolar mania, submitted to the FDA as part of a new drug application for Fanapt. The FDA has set a target action date of April 2, 2024, for its decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) Submits Comment Letter on FDA's Draft Guidance Document
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) to present at J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
-
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen). PONVORY® is approved by the FDA and Health Canada to treat adults with relapsing forms of multiple sclerosis. In a clinical study, PONVORY® showed superiority to another approved drug for MS and was associated with fewer MRI lesions. It has a proven safety profile with over 10 years of data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
-
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) announced that the FDA has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. The FDA has set September 18, 2024, as the target date for its decision. If approved, tradipitant will be the first novel drug for gastroparesis in over 40 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) to participate in Stifel 2023 Healthcare Conference on November 14 and Jefferies 2023 London Healthcare Conference on November 16, with live access on corporate website. Investors advised to register early and access archived conferences for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
-
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) reports total revenues of $147.4 million in the first nine months of 2023, with a focus on pipeline advancements and regulatory plans. Despite challenges with the at-risk launch of a generic Hetlioz product, the company expects FDA decisions on two sNDAs for bipolar I disorder and insomnia in 2024. Financially, net product sales decreased by 22% compared to the same period in 2022, with HETLIOZ® net product sales declining by 34%. The company's net income improved from a loss in 2022 to $4.9 million in the first nine months of 2023, with Cash at $489.9 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.94%
Tags
-
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) will release its third quarter 2023 results on November 8, 2023, after the market closes. The company will host a conference call at 4:30 PM ET on the same day to discuss the financial results and other corporate activities. The call can be accessed by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) with passcode 9774278. The call will also be broadcasted and archived on Vanda's website. A replay of the call will be available until November 15, 2023, with the call-in numbers 1-800-770-2030 (domestic) and 1-609-800-9909 (international) with passcode 9774278.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
Rhea-AI Summary
Vanda Pharmaceuticals to file petition against Teva Pharmaceuticals and Apotex Inc. in HETLIOZ® patent litigation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
Vanda Pharmaceuticals Inc

Nasdaq:VNDA

VNDA Rankings

VNDA Stock Data

246.26M
52.05M
5.32%
92.21%
5.22%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Washington

About VNDA

vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.